Altimmune heads into its third-quarter report with an awkward contradiction to resolve. Last quarter, management delivered almost everything it had promised: strongly positive Phase 2 data in alcohol use disorder, the launch of its PERFORMA Phase 3 trial in MASH, and a balance sheet of roughly $519 million. Yet the stock has fallen about 35% since that report, trailing the S&P 500 by some 30 percentage points. When the company reports before the open on November 12, the numbers will matter less than whether management can show that the clinical momentum is real and that the funding plan for its next pivotal program holds together.
On the income statement, the bar is modest and mostly about spending. Wall Street expects a loss of $0.14 per share, narrower than the $0.21 loss from a year ago, a roughly 33% improvement that largely reflects a bigger share count after this year's financings rather than any change in the business. There is no meaningful revenue to model. The more telling comparison is sequential. The consensus loss is slightly wider than last quarter's $0.12, consistent with costs rising as a Phase 3 trial spanning about 300 sites ramps. Altimmune has run a steady net loss of roughly $23 million a quarter, so a noticeable step-up in research spending would not be bad news. It would likely be the clearest financial sign that PERFORMA is enrolling with some vigor.
That enrollment pace is the first test of last quarter's story. Management described a company becoming a late-stage developer that executes quickly, noting that PERFORMA began just three months after the financing closed. Updates on site activation, patient recruitment and the use of AI-assisted pathology would support that claim. The risk management itself flagged is competition for patients and sites, since several other MASH Phase 3 programs, including semaglutide, cervodutide and FGF21 drugs, are recruiting from the same pool. Any hint of slower enrollment would directly threaten the 52-week readout in 2029, which the current cash runway is built to reach.
The second test involves alcohol use disorder, which has turned into Altimmune's most interesting new opportunity. The Reclaim trial hit its primary endpoint and both secondary endpoints the FDA considers registrational. It also showed 9.1% weight loss and an early signal of liver benefit, which supports management's idea of a broader liver franchise. The open questions are practical. The company has not given a timeline or design for an AUD Phase 3, which depends on an end-of-Phase-2 meeting with the FDA, and the trial is not yet funded. Management said it intends to pay for it through royalty, debt or partnership arrangements rather than selling more stock. Progress on scheduling or completing that FDA meeting, or concrete signs of non-dilutive financing talks, would strengthen the case. Silence, or any suggestion that equity is back on the table, would likely deepen the market's skepticism.
The tape already reflects plenty of doubt. At $1.97, the shares sit just above their post-earnings low of $1.91 and far below the 200-day moving average near $3.24, after trading as high as $3.55 shortly after the last report. Sentiment readings are mildly bearish and essentially unchanged from a quarter ago, which suggests a steady, cautious mood rather than outright capitulation. A stock near its lows with fresh positive data can react sharply to reassurance, but it can also break support if the update disappoints.
In the end, this report is about credibility rather than earnings per share. If Altimmune can show PERFORMA enrolling on schedule, give a clearer path for the AUD Phase 3 and point to a realistic non-dilutive way to pay for it, the improving narrative from last quarter stays intact. If those answers stay vague, the recent sell-off may start to look like the market's verdict rather than an overreaction.